NASDAQ$RLAY
Relay Therapeutics Inc. · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported first quarter 2024 financial results and corporate highlights.
Relay Therapeutics reported a revenue of $10.0 million for the first quarter of 2024, primarily due to a milestone payment from Genentech. The company's cash, cash equivalents, and investments totaled approximately $750 million, expected to fund operations into the second half of 2026. Net loss for the quarter was $81.4 million, or $0.62 per share.
- Cash, cash equivalents, and investments totaled approximately $750 million at the end of Q1 2024, expected to fund operations into the second half of 2026.
- Revenue was $10.0 million for the first quarter of 2024, compared to $0.2 million for the first quarter of 2023, driven by a milestone payment from Genentech.
- Research and development expenses were $82.4 million for the first quarter of 2024, compared to $82.8 million for the first quarter of 2023.
- Net loss was $81.4 million for the first quarter of 2024, or $0.62 per share, compared to a net loss of $94.2 million for the first quarter of 2023, or $0.78 per share.
Headline financials
Revenue & EPS history
Relay Therapeutics · Revenue · Quarterly
$10M
Revenue by segment
Relay Therapeutics · $25.2M total across 1 segment · Q3 2023
- License and Other Revenue$25.2M—100.0%
Forward guidance
Relay Therapeutics anticipates several milestones in 2024, including RLY-2608 data updates, lirafugratinib updates, and disclosing new pre-clinical programs.
Tailwinds
- RLY-2608 + fulvestrant data update in the second half of 2024
- RLY-2608 + fulvestrant + ribociclib initial safety data in the second half of 2024
- Lirafugratinib tumor agnostic data and regulatory update in the second half of 2024
- Disclose new program(s) in 2024
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+0.2%
Avg return
Earnings day
-0.4%
Avg return
5 days after
-0.5%
Avg return
30 days after
57%
13 / 23 earnings
Positive
+11.7%
Q4 2025
Best reaction
-19.5%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.7% | -2.5% | +11.1% | |
| Q4 2025 | +11.7% | +10.8% | +4.8% | |
| Q3 2025 | -7.4% | -5.5% | +17.6% | |
| Q1 2025 | -4.8% | -9.6% | -2.4% | |
| Q4 2024 | -13.3% | -14.9% | -27.5% | |
| Q3 2024 | +3.2% | +3.5% | -22.5% | |
| Q2 2024 | -6.8% | -5.6% | -8.6% | |
| Q1 2024 | +5.7% | +1.2% | -3.8% | |
| Q4 2023 | -4.6% | -1.8% | -25.7% | |
| Q3 2023 | +10.1% | +19.3% | +27.4% | |
| Q2 2023 | +7.8% | +3.5% | -3.2% | |
| Q1 2023 | +0.5% | -5.3% | +2.3% | |
| Q4 2022 | -3.6% | -8.8% | -13.5% | |
| Q3 2022 | -4.3% | -6.8% | -12.4% | |
| Q2 2022 | +3.8% | -1.6% | +31.7% | |
| Q1 2022 | -19.5% | -33.5% | -31.6% | |
| Q4 2021 | +11.5% | +17.4% | +40.1% | |
| Q3 2021 | +1.7% | +0.6% | -19.6% | |
| Q2 2021 | +1.0% | +0.2% | -1.7% | |
| Q1 2021 | +5.7% | +8.5% | +23.9% | |
| Q4 2020 | -2.3% | +2.0% | -13.5% | |
| Q3 2020 | +0.5% | +13.5% | +5.7% | |
| Q2 2020 | +8.0% | +5.3% | +8.5% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro